Cargando…

Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma

Ovarian cancer patients with homologous recombination deficiency (HRD) tumors would benefit from PARP inhibitor (PARPi) therapy. However, patients with HRD tumors account for less than 50% of the whole cohort, so new biomarkers still need to be developed. Based on the data from the SNP array and som...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Zhiwen, Zhao, Qingguo, Lv, Bin, Qu, Xinyu, Han, Xiao, Wang, Hongyan, Qiu, Junjun, Hua, Keqin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8131501/ https://www.ncbi.nlm.nih.gov/pubmed/34047476 http://dx.doi.org/10.1002/ctm2.399

Ejemplares similares

CXCL10 potentiates immune checkpoint blockade therapy in homologous recombination-deficient tumors
por: Shi, Zhiwen, et al.
Publicado: (2021)

Gastric metastasis of ovarian serous cystadenocarcinoma
por: Yang, Shiqiang
Publicado: (2018)

Serous cystadenocarcinoma of the spleen
por: Chou, Chung Kuao, et al.
Publicado: (2017)

Genome-Wide Identification and Validation of Gene Expression Biomarkers in the Diagnosis of Ovarian Serous Cystadenocarcinoma
por: Zalfa, Francesca, et al.
Publicado: (2022)

KRT19 is a Promising Prognostic Biomarker and Associates with Immune Infiltrates in Serous Ovarian Cystadenocarcinoma
por: Sun, Zhe, et al.
Publicado: (2023)

Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer
por: Bouberhan, Sara, et al.
Publicado: (2020)

Mining TCGA database for gene expression in ovarian serous cystadenocarcinoma microenvironment
por: Xu, Youzheng, et al.
Publicado: (2021)

Stem Cell-Associated Signatures Help to Predict Diagnosis and Prognosis in Ovarian Serous Cystadenocarcinoma
por: Li, Li, et al.
Publicado: (2023)

Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma
por: Takaya, Hisamitsu, et al.
Publicado: (2020)

Increased Expression of LYNX1 in Ovarian Serous Cystadenocarcinoma Predicts Poor Prognosis
por: Liu, Hui, et al.
Publicado: (2020)

An Immune-Related Gene-Based Signature as Prognostic Tool in Ovarian Serous Cystadenocarcinoma
por: Shi, Fengjuan, et al.
Publicado: (2021)

A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma
por: Guo, Wenna, et al.
Publicado: (2018)

Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer
por: Patel, Jai N., et al.
Publicado: (2018)

Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status
por: Li, Yongmei, et al.
Publicado: (2022)

Low expression of acyl-CoA thioesterase 13 is associated with poor prognosis in ovarian serous cystadenocarcinoma
por: Lv, Xiaofeng, et al.
Publicado: (2023)

Estimation of Prognostic Marker Genes by Public Microarray Data in Patients with Ovarian Serous Cystadenocarcinoma
por: Yang, San-Duk, et al.
Publicado: (2016)

A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma
por: Liu, Li-Wei, et al.
Publicado: (2016)

Expression of Yes-associated protein 1 and its clinical significance in ovarian serous cystadenocarcinoma
por: Cho, Sang Yeon, et al.
Publicado: (2017)

Development and Validation of an RNA-Binding Protein-Based Prognostic Model for Ovarian Serous Cystadenocarcinoma
por: He, Yunan, et al.
Publicado: (2020)

Comprehensive analysis of LDHAP5 pseudogene expression and potential pathogenesis in ovarian serous cystadenocarcinoma
por: Lin, Shitong, et al.
Publicado: (2020)

Assessment of Significant Pathway Signaling and Prognostic Value of GNG11 in Ovarian Serous Cystadenocarcinoma
por: Jiang, Ming-Min, et al.
Publicado: (2021)

TRPs in Ovarian Serous Cystadenocarcinoma: The Expression Patterns, Prognostic Roles, and Potential Therapeutic Targets
por: Zhang, Cheng, et al.
Publicado: (2022)

Pancreatic serous cystadenocarcinoma with invasive growth into the colon and spleen
por: Cho, Wontae, et al.
Publicado: (2011)

Comprehensive analysis of the expression of sodium/potassium-ATPase α subunits and prognosis of ovarian serous cystadenocarcinoma
por: Huang, Wei, et al.
Publicado: (2020)

Gene Expression Subtyping Reveals Immune alterations:TCGA Database for Prognosis in Ovarian Serous Cystadenocarcinoma
por: Feng, Chunxia, et al.
Publicado: (2021)

A novel ferroptosis related gene signature is associated with prognosis in patients with ovarian serous cystadenocarcinoma
por: Yu, Zhixiang, et al.
Publicado: (2021)

Long non-coding RNA FOXP4-AS1 is a prognostic biomarker and associated with immune infiltrates in ovarian serous cystadenocarcinoma
por: Liao, Cheng, et al.
Publicado: (2021)

Pancreatic Serous Cystadenocarcinoma: A Case Report and Review of the Literature
por: King, Jonathan C., et al.
Publicado: (2009)

Serous cystadenocarcinoma of the pancreas: report of a case and management reflections
por: Bramis, K, et al.
Publicado: (2012)

Hepatic resection of metastatic tumor from serous cystadenocarcinoma of the ovary.
por: Lee, Jong Hoon, et al.
Publicado: (2002)

Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer
por: Lee, Jung-Min, et al.
Publicado: (2015)

RAD51 as a biomarker for homologous recombination deficiency in high‐grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test
por: Kramer, Claire JH, et al.
Publicado: (2023)

Development of Serous Ovarian Cancer is Associated with the Expression of Homologous Recombination Pathway Proteins
por: Ye, Qingqing, et al.
Publicado: (2014)

Biomarkers for Homologous Recombination Deficiency in Cancer
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2021)

Dynamically Accumulating Homologous Recombination Deficiency Score Served as an Important Prognosis Factor in High-Grade Serous Ovarian Cancer
por: Su, Rongjia, et al.
Publicado: (2021)

A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer Diagnosis
por: Guarischi-Sousa, Rodrigo, et al.
Publicado: (2023)

Serous cystadenocarcinoma of the mesentery in a man: case report and review of literature
por: Obuchi, Toru, et al.
Publicado: (2014)

Identification and validation of a novel anoikis-related signature for predicting prognosis and immune landscape in ovarian serous cystadenocarcinoma
por: Zhu, Yu-Ting, et al.
Publicado: (2023)

Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
por: Feng, Zheng, et al.
Publicado: (2023)

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers
por: Watkins, Johnathan A, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_c71fjmmotbo52kmk40o5t07llu